TY - JOUR
T1 - GZD824 inhibits GCN2 and sensitizes cancer cells to amino acid starvation stress
AU - Kato, Yu
AU - Kunimasa, Kazuhiro
AU - Takahashi, Mizuki
AU - Harada, Ayaka
AU - Nagasawa, Ikuko
AU - Osawa, Masanori
AU - Sugimoto, Yoshikazu
AU - Tomida, Akihiro
N1 - Funding Information:
This work was supported in part by the Japan Society for the Promotion of Science (JSPS) KAKENHI [Grants 16H04717, 18K19486, and 19H03526] and the Nippon Foundation. The authors declare no conflicts of interest. https://doi.org/10.1124/molpharm.120.000070. s This article has supplemental material available at molpharm. aspetjournals.org.
Publisher Copyright:
© 2020 by The American Society for Pharmacology and Experimental Therapeutics.
PY - 2020/12
Y1 - 2020/12
N2 - Eukaryotic initiation factor 2a (eIF2a) kinase general control nonderepressible 2 (GCN2) drives cellular adaptation to amino acid limitation by activating the integrated stress response that induces activating transcription factor 4 (ATF4). Here, we found that a multikinase inhibitor, GZD824, which we identified using a cell-based assay with ATF4 immunostaining, inhibited the GCN2 pathway in cancer cells. Indeed, GZD824 suppressed GCN2 activation, eIF2a phosphorylation, and ATF4 induction during amino acid starvation stress. However, at lower nonsuppressive concentrations, GZD824 paradoxically stimulated eIF2a phosphorylation and ATF4 expression in a GCN2-dependent manner under unstressed conditions. Such dual properties conceivably arose from a direct effect on GCN2, as also observed in a cell-free GCN2 kinase assay and shared by a selective GCN2 inhibitor. Consistent with the GCN2 pathway inhibition, GZD824 sensitized certain cancer cells to amino acid starvation stress similarly to ATF4 knockdown. These results establish GZD824 as a multikinase GCN2 inhibitor and may enhance its utility as a drug under development.
AB - Eukaryotic initiation factor 2a (eIF2a) kinase general control nonderepressible 2 (GCN2) drives cellular adaptation to amino acid limitation by activating the integrated stress response that induces activating transcription factor 4 (ATF4). Here, we found that a multikinase inhibitor, GZD824, which we identified using a cell-based assay with ATF4 immunostaining, inhibited the GCN2 pathway in cancer cells. Indeed, GZD824 suppressed GCN2 activation, eIF2a phosphorylation, and ATF4 induction during amino acid starvation stress. However, at lower nonsuppressive concentrations, GZD824 paradoxically stimulated eIF2a phosphorylation and ATF4 expression in a GCN2-dependent manner under unstressed conditions. Such dual properties conceivably arose from a direct effect on GCN2, as also observed in a cell-free GCN2 kinase assay and shared by a selective GCN2 inhibitor. Consistent with the GCN2 pathway inhibition, GZD824 sensitized certain cancer cells to amino acid starvation stress similarly to ATF4 knockdown. These results establish GZD824 as a multikinase GCN2 inhibitor and may enhance its utility as a drug under development.
UR - http://www.scopus.com/inward/record.url?scp=85095799543&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095799543&partnerID=8YFLogxK
U2 - 10.1124/MOLPHARM.120.000070
DO - 10.1124/MOLPHARM.120.000070
M3 - Article
C2 - 33033108
AN - SCOPUS:85095799543
SN - 0026-895X
VL - 98
SP - 669
EP - 676
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 6
ER -